Your browser doesn't support javascript.
loading
Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?
van den Hoogen, Lotus L; Smits, Gaby; van Hagen, Cheyenne C E; Wong, Denise; Vos, Eric R A; van Boven, Michiel; de Melker, Hester E; van Vliet, Jeffrey; Kuijer, Marjan; Woudstra, Linde; Wijmenga-Monsuur, Alienke J; GeurtsvanKessel, Corine H; Stoof, Susanne P; Reukers, Daphne; Wijsman, Lisa A; Meijer, Adam; Reusken, Chantal B E M; Rots, Nynke Y; van der Klis, Fiona R M; van Binnendijk, Robert S; den Hartog, Gerco.
Afiliación
  • van den Hoogen LL; Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. Electronic address: Lotus.van.den.hoogen@rivm.nl.
  • Smits G; Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • van Hagen CCE; Centre for Infectious Diseases, Epidemiology and Surveillance, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Wong D; Centre for Infectious Diseases, Epidemiology and Surveillance, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Vos ERA; Centre for Infectious Diseases, Epidemiology and Surveillance, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • van Boven M; Centre for Infectious Diseases, Epidemiology and Surveillance, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • de Melker HE; Centre for Infectious Diseases, Epidemiology and Surveillance, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • van Vliet J; Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Kuijer M; Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Woudstra L; Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Wijmenga-Monsuur AJ; Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • GeurtsvanKessel CH; Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands.
  • Stoof SP; Department of Medical Microbiology Comicro, Dijklander ziekenhuis, Hoorn, the Netherlands.
  • Reukers D; Centre for Infectious Diseases Research, Diagnostics and Laboratory Surveillance, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Wijsman LA; Centre for Infectious Diseases Research, Diagnostics and Laboratory Surveillance, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Meijer A; Centre for Infectious Diseases Research, Diagnostics and Laboratory Surveillance, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Reusken CBEM; Centre for Infectious Diseases Research, Diagnostics and Laboratory Surveillance, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Rots NY; Centre for Infectious Diseases Research, Diagnostics and Laboratory Surveillance, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • van der Klis FRM; Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • van Binnendijk RS; Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • den Hartog G; Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Vaccine ; 40(15): 2251-2257, 2022 04 01.
Article en En | MEDLINE | ID: mdl-35287986
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Vaccine Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Vaccine Año: 2022 Tipo del documento: Article